Previously, Dr. Dunsire led the Novartis U.S. Oncology business and played a critical role in the broad development and launch of successful products such as Zometa^®, Femara^® and Gleevec^®. Notably, Dr. Dunsire managed 12 product launches and built the business from approximately $50 million to $2.1 billion in revenues over 10 years. Dr. Dunsire also was responsible in the U.S. for managing the merger and significant growth of the combined Sandoz Pharmaceuticals and Ciba-Geigy oncology businesses. Earlier in her career, she was a clinical researcher responsible for the implementation of global Phase II and Phase III studies across multiple therapeutic areas, including immunology, endocrinology, neurology, dermatology, oncology and transplantation.

Dr. Dunsire graduated from medical school at the University of Witwatersand in Johannesburg, South Africa. In 2006, she was also awarded a Doctor of Science, Honoris Causa, from Worcester Polytechnic Institute. Currently, Dr. Dunsire is a board member of the Pharmaceutical Research and Manufacturers of America (PhRMA), Biotechnology Industry Organization (BIO), Allergan, Inc. and the G&P Foundation for Cancer Research. In 2001, she was the recipient of the American Cancer Society Excalibur award, the 2000 recipient of the Health Care Business Women's Association Rising Star award and also the Creative Spirit award from the Creative Center for Women with Cancer.

Previously, Dr. Bianchi built commercial and sales organizations, launched major brands, delivered sustained growth, and managed collaborations with partner companies. Dr. Bianchi spent the last five years at sanofi-aventis, where he led a $2 billion U.S. oncology business unit with the well-known brands Eloxatin^®, Taxotere^® and Elitek^®. Dr. Bianchi headed the internal medicine and central nervous system business unit at sanofi-synthelabo with sales of $1.2 billion, including a 20 percent annual sales growth for Ambien^®. Additionally, Dr. Bianchi served as President of Europe and Senior Vice President of Global Marketing and Business Development for SangStat Medical Corporation, a global biotechnology firm focused on organ transplant that was later acquired by Genzyme. Earlier in his career, Dr. Bianchi served as Vice President of Global Marketing for Rhone-Poulenc Rorer, where he led many of the commercial efforts for the market-leading antithrombotic, Lovenox^®.

A native of France, Dr. Bianchi also is a naturalized American citizen. He earned a medical degree from the University of Reims-Champagne in France and an M.B.A. from the Wharton School at the University of Pennsylvania. Currently, Dr. Bianchi is a board member of Penwest Pharmaceuticals.

In 2003 Dr. Bolen was appointed Senior Vice President of Research and Drug Discovery, a role in which he heads all biological research and related functions as well as all drug discovery functions. Dr. Bolen was appointed Chief Scientific Officer in 2006.

Prior to joining Millennium, Dr. Bolen was Vice President of Oncologic Diseases at Hoechst Marion Roussel. Previously, Dr. Bolen served as the Director of the Cellular Signaling Department at the DNAX Research Institute of Molecular and Cellular Biology (a functional genomics and research division of Schering-Plough) in Palo Alto, California. At DNAX, Dr. Bolen was involved in immunology and oncology research and development efforts. Earlier in his career, Dr. Bolen was Executive Director of Oncology Drug Discovery at the Bristol-Myers Squibb Pharmaceutical Research Institute, Professor and Member of the Graduate Faculty at Princeton University in the Department of Molecular Biology. During this period, Dr. Bolen also served as a Graduate Advisor in the Physiology and Neurobiology Program at the Robert Wood Johnson Medical School.

Dr. Bolen graduated from the University of Nebraska with a B.S. degree in Microbiology and Chemistry and a Ph.D. in Immunology. He pursued post-doctoral training in Molecular Virology at the Kansas State University Cancer Center, where his research was directed towards analysis of the DNA Tumor Virus, Polyoma. Dr. Bolen then joined the National Institutes of Health as a member of the Laboratory of Molecular Microbiology, where his research focus turned to the protein tyrosine kinase class of oncogenes. A founding member of the Laboratory of Tumor Virus Biology, Dr. Bolen also joined the National Cancer Institute and was appointed Chief of the Biochemical Oncology Section.

Dr. Bolen received the National Institutes of Health Award for Meritorious Research in 1990 for his key contributions to the discovery of the normal physiologic functions of the src group of protein tyrosine kinase oncogenes as key regulators of the immune system. Dr. Bolen has published more than 200 peer-reviewed scientific articles and book chapters and has served on several journal editorial boards, including the Journal of Virology, Molecular and Cellular Biology, and Current Topics in Virology. Dr. Bolen has served on numerous study sections, panels and committees for the National Institutes of Health, the National Aeronautics and Space Administration, and the Howard Hughes Medical Institute. Dr. Bolen also served as a member of the Scientific Advisory Board for the Center for Advanced Biotechnology and Medicine at the University of Medicine and Dentistry of Rutgers University and is currently a member of the Scientific Advisory Board for the Hollings Cancer Center.

In July, 2004, Ms. Fanucci was appointed Senior Vice President and Chief Financial Officer, where she is responsible for developing the overall strategy and business plan.

Prior to joining Millennium, Ms. Fanucci was Vice President, Corporate Development and Strategy at Genzyme. Earlier in her career, Ms. Fanucci was a Vice President and Managing Director at Arthur D. Little, Inc., where she consulted with pharmaceutical firms on corporate and business unit strategy.

Ms. Fanucci earned a bachelor's degree in Pharmacy from West Virginia University and an M.B.A. from Northeastern University.

Most recently, Mr. Gansler was Vice President of Human Resources at Synta Pharmaceuticals, a biotechnology company focused on oncology and inflammation. Previously, he served as Senior Vice President of Human Resources for the Covanta Energy Corporation.

He also has held many senior human resources positions and was a member of the management board for several companies within the Johnson & Johnson Family of Companies, including DePuy, Inc., J&J Healthcare Systems, J&J Vision Products and J&J Orthopedics. At J&J, Mr. Gansler developed and implemented human resource strategies that supported businesses with annual revenue from $100 million to more than $1 billion; shaped worldwide leadership development and succession planning; and established recognition and incentive programs to enhance a high involvement, team-oriented corporate culture. He began his career in labor relations at General Motors Corporation.

Mr. Gansler earned a bachelor's degree in Industrial Administration from Kettering University as well as M.B.A. and law degrees from Seton Hall University.

Previously, Ms. Keating served as Executive Vice President of Operations and Finance and as a board member at Hydra Biosciences, Inc., a biopharmaceutical company that develops drugs targeting novel ion channels. One of the co-founders in 2001, Ms. Keating was President and CEO. Prior to this position, Ms. Keating served as Senior Vice President, General Counsel and Secretary at Iomega Corporation. She also served on the executive team at Sybase Inc., holding the positions of Senior Vice President, General Counsel and Secretary. Earlier in her career, Ms. Keating practiced law at McCutchen, Doyle, Brown and Enersen.

Ms. Keating earned a bachelor's degree in Economics from the University of California at Berkeley and received her J.D. from the University of California, Hastings College of the Law.

Prior to Millennium, Ms. Protopapas held various positions in engineering, marketing and business development. She holds a bachelor's degree in Engineering from Princeton University, a master's degree in Engineering from MIT, and an M.B.A. from Stanford Business School.

Prior to joining Millennium, Dr. Simonian was Vice President of Clinical Research at Biogen, where she was responsible for the clinical development of AVONEX^® (Interferon beta-1a), Tysabri (natalizumab) and their oncology programs.

Dr. Simonian earned a bachelor's degree in Biology from Princeton University and received her M.D. from the University of Pennsylvania, School of Medicine. She completed her medical residency at Massachusetts General Hospital (MGH) in Neurology, was an Assistant Clinical Professor at MGH and Harvard Medical School, and is board-certified in Neurology.

Dr. Simonian chairs the Portfolio Review Committee at Millennium. She also is a board member of Arqule Pharmaceuticals. In 1995, Dr. Simonian was awarded the Physician Scientist award from the National Institutes of Health and in 1994 named an Ellison Scholar. In 1988, she was awarded the Academic Medicine, Clinical Medicine and Neurology prizes from the University of Pennsylvania, School of Medicine.

Prior to joining Millennium, Dr. Smith was a Vice President at Pharmacia, where he led a global metabolism and investigative sciences department of more than 300 scientists. Previously at Searle/Monsanto, Dr. Smith led the Metabolism and Safety Evaluation department. In this role he was responsible for the preclinical development of the Cox-2 inhibitors Celebrex^® and Bextra^®; the antimineralocorticoid Inspra^® and the glycoprotein IIb/IIIa antagonists, xemilofiban and orbofiban. Earlier in his career, Dr. Smith served as a Senior Research Toxicologist and Research Fellow in the Safety Assessment Department at Merck Research Laboratories, where he developed extensive project team experience working with leading pharmaceutical agents, including Mevacor^®, Zocor^®, Hyzaar^®, Fosamax^® and Proscar^®.

Dr. Smith earned a bachelor's degree in Biology from Fairfield University, received a Ph.D. in Pharmacology and Toxicology from the University of Arizona, and completed a post-doctoral fellowship in Biochemical Toxicology at Smith Kline and French Laboratories.

Dr. Dunsire joined Millennium in July, 2005 with nearly 20 years of experience in commercial, operational, clinical and scientific aspects of a world-leading pharmaceutical business. Her vision for Millennium is to establish a vibrant, growing biotechnology company, which discovers and develops new medicines that change standards of care in cancer and inflammation.

Previously, Dr. Dunsire led the Novartis U.S. Oncology business and played a critical role in the broad development and launch of successful products such as Zometa^®, Femara^® and Gleevec^®. Notably, Dr. Dunsire managed 12 product launches and built the business from approximately $50 million to $2.1 billion in revenues over 10 years. Dr. Dunsire also was responsible in the U.S. for managing the merger and significant growth of the combined Sandoz Pharmaceuticals and Ciba-Geigy oncology businesses. Earlier in her career, she was a clinical researcher responsible for the implementation of global Phase II and Phase III studies across multiple therapeutic areas, including immunology, endocrinology, neurology, dermatology, oncology and transplantation.

Dr. Dunsire graduated from medical school at the University of Witwatersand in Johannesburg, South Africa. In 2006, she was also awarded a Doctor of Science, Honoris Causa, from Worcester Polytechnic Institute. Currently, Dr. Dunsire is a board member of the Pharmaceutical Research and Manufacturers of America (PhRMA), Biotechnology Industry Organization (BIO), Allergan, Inc. and the G&P Foundation for Cancer Research. In 2001, she was the recipient of the American Cancer Society Excalibur award, the 2000 recipient of the Health Care Business Women's Association Rising Star award and also the Creative Spirit award from the Creative Center for Women with Cancer.

Mr. Friel currently serves as Chief Executive Officer (since February 2008) and President (since August 2007) of PerkinElmer, Inc. He served as Chief Operating Officer of PerkinElmer from August 2007 to February 2008. Prior to that he was Vice Chairman of PerkinElmer and President of its Life and Analytical Sciences business. PerkinElmer, Inc., is a global technology leader in health services and photonics with annual revenues of $1.6 billion. Prior to being appointed Vice Chairman, Friel served as Executive Vice President and Chief Financial Officer of PerkinElmer, Inc. He joined PerkinElmer in 1999 and was one of the primary architects of the Company's transformation into a global technology leader in health sciences and photonics. Previously, he held several senior management positions at AlliedSignal, Inc., now Honeywell International. Friel also serves on the Boards of PerkinElmer, Inc. and Fairchild Semiconductor.

Mr. Heidrich is a partner at Mayfield, a California-based venture capital firm which he joined in 1982. Previously, he served as vice president of Wood River Capital, a New York City-based venture capital firm. Currently, Mr. Heidrich serves on the board of directors at a number of Mayfield portfolio companies including Millennium Pharmaceuticals, Inc. and Cytokinetics. He also served as chairman of the board of directors of Tularik until it was acquired by Amgen. He earned a Bachelor's degree in human biology from Stanford University and an M.B.A. from Columbia University.

Dr. Homcy is president and chief executive officer of Portola Pharmaceuticals, Inc. Dr. Homcy joined Millennium in 2002 as president, research and development and from January 2003 to November 2003 served as senior R&D advisor. From 1995 to 2002, he served as executive vice president, research and development of COR Therapeutics, Inc. and as a director of COR since January 1998. Since 1997, Dr. Homcy has been clinical professor of medicine at the University of California at San Francisco Medical School and an attending physician at the San Francisco VA Hospital. Previously, Dr. Homcy was president of the medical research division of American Cyanamid Company-Lederle Laboratories (now a division of Wyeth-Ayerst Laboratories), executive director of the cardiovascular and central nervous system research section at Lederle Laboratories, and an attending physician at The Presbyterian Hospital, College of Physicians and Surgeons, at Columbia University and at Massachusetts General Hospital. He also was appointed an Associate Professor of Medicine at Harvard Medical School. Dr. Homcy is a member of the boards of directors of Kosan Biosciences and Portola Pharmaceuticals. He received his B.A. and M.D. degrees from the Johns Hopkins University.

Currently, Dr. Kucherlapati is the scientific director of the Harvard-Partners Center for Genetics and Genomics. He is also the Paul C. Cabot Professor of Genetics and a professor of medicine at Harvard Medical School. Formerly, Dr. Kucherlapati was chairman of molecular genetics and a professor at Albert Einstein College of Medicine in New York. He was a member of the National Advisory Committee for Human Genome Research at the National Institutes of Health (NIH) and editor-in-chief of the journal Genomics. He currently serves on the Editorial Board of the New England Journal of Medicine. Dr. Kucherlapati obtained a Doctoral in Genetics from the University of Illinois.

Jeffrey Leiden, MD, Ph.D., has more than 20 years of experience in the biomedical and pharmaceutical sectors. Dr. Leiden was President and COO of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Abbott Board of Directors and the TAP Board of Directors from 2000-2006. From 1987-2000 Dr. Leiden held several academic appointments including Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. During his academic career, Dr. Leiden was involved in starting several biotechnology companies including Vical and Cardiogene. He is an elected member of both the American Academy of Arts and Sciences, and the Institute of Medicine of the National Academy of Sciences.

Dr. Leiden has recently led financing on behalf of Clarus Ventures and is Chairman of the Board of Variation Biotechnologies, Inc. He is also a non-executive director of Shire plc and a member of the Board of Trustees of the Ravinia Festival and the University of Pennsylvania School of Medicine.

Dr. Leiden received both his medical degree and PhD from the University of Chicago and an honorary MA from Harvard University.

Mark J. Levin is presently a Partner in Third Rock Ventures, a venture capital firm. In the past, Mr. Levin served as the President and Chief Executive Officer of Millennium Pharmaceuticals, Inc. from its inception to 2005. Mr. Levin also served as chairman of the board of directors of Millennium from March 1996 to 2005.

In 2002, he became a peer-appointed member of the prestigious National Academy of Engineers. From 1987 to 1994, Mr. Levin was a partner at Mayfield Fund, a venture capital firm, and co-director of its Life Science Group. While employed at Mayfield, Mr. Levin was the founding chief executive officer of several biotechnology and biomedical companies, including Cell Genesys, Inc., CytoTherapeutics, Inc., Tularik, Inc. and Focal, Inc. From 1981 to 1987 he served as the manager of process engineering and as a project leader at Genentech, Inc. From 1974 to 1977, he served as a biochemical engineer at Eli Lilly & Co.

Mr. Levin holds an M.S. in chemical and biomedical engineering from Washington University.

Mr. Selby is a Senior Managing Director at Perseus, L.L.C. Previously, he served as the president and chief executive officer of TransForm Pharmaceuticals, Inc. and prior to that as head of Consumer Internet Business at Citigroup/Citicorp. Also, Mr. Selby was head of the global pharmaceuticals practice at McKinsey & Company, the international management consulting firm, and the interim chief operating officer of the New York Blood Center. He is also on the board of the Memorial Sloan-Kettering Cancer Center. Mr. Selby holds a bachelor's degree in architecture from Yale College, and he received his MBA from the Harvard Graduate School of Business Administration.

Mr. Weg is a founder and the chairman of Clearview Projects, a company dedicated to representing biopharmaceutical clients on strategic transactions to maximize the value of the technologies and products in their portfolios. He has over 33 years of experience in the pharmaceutical industry with Merck, Sharp & Dohme and Bristol-Myers Squibb. Since 1993, he was president, Worldwide Medicines Group, Bristol-Myers Squibb Company, responsible for all ethical pharmaceuticals and over-the-counter medicines on a global basis. Mr. Weg was elected to the board of directors and named as an executive vice president of Bristol-Myers Squibb Company in May 1995. In May 1999, he was elected vice chairman of the board. He retired in February 2001. Currently, Mr. Weg serves on the Board of Directors of AVEO Pharmaceuticals, Inc. and Vice Chairman of the Board at Fox Chase Cancer Center. He is a member of the Genetics Advisory Council of the Harvard-Partners Center for Genetics and Genomics. He holds a B.A. in English Literature from Dartmouth, an M.B.A. from Columbia University, and an honorary Doctor of Philosophy from the Medical University of Southern Africa.

Dr. Wild is a general partner of Bows Pharmaceuticals AG. He was chairman of MedPointe, Inc. a specialty pharmaceutical company, from September 2001 until its merger with Meda AB in August 2007, and he served as MedPointe's chief executive officer from 2001 to 2006. Prior to joining MedPointe, Dr. Wild served as executive vice president of Warner-Lambert and president of its pharmaceutical sector until the merger with Pfizer in June 2000. During his tenure, Dr. Wild had worldwide responsibility for Warner-Lambert's pharmaceutical commercial operations and research and development. Before joining Warner-Lambert in 1995, Dr. Wild spent 22 years with Schering-Plough Corporation in a number of positions across the globe, culminating as president of Schering-Plough's Japanese operations. Dr. Wild also served at Sandoz AG as a development chemist, where he worked on optimization and simulation of chemical processes. Dr. Wild is a member of the Board of Advisors to the Joseph L. Mailman School of Public Health at Columbia University, a Trustee of the Healthcare Institute of New Jersey, past Chairman of the International Section of Pharmaceutical Research and Manufacturers of America, and past Governor of the American Chamber of Commerce in Japan. Dr. Wild graduated from the University of York with a B.A. honors degree in Chemistry and received a Ph.D. in Physical Chemistry from the University of Cambridge.